Serum Institute of India who has recently announced its collaboration with Codagenix in developing a COVID-19 vaccine expects to progress to the human trial phase within the next 6 months as they have already progressed into pre-clinical tests.
Serum Institute of India has been changing the game in the vaccine manufacturing industry with its groundbreaking advancements and has become the world’s largest vaccine manufacturer by the number of doses produced and sold globally.
Mr. Poonawalla (CEO of Serum Institute of India) says that the vaccine has been developed using synthetic virus made from the laboratory that will greatly reduce the amount of time taken in building a shield against the virus.
They are excited that their combined efforts with Codagenix are showing good results that can potentially save millions of people around the world.
COVID-19 has been affecting the lives of millions of people around the world with the sudden outbreak of it thus, a countermeasure must be placed.
While several efforts have been made in the stride to finding a cure as well as in controlling the outbreak, this will be the first vaccine-virus strain to progress to the pre-clinical trial phase.